The infectious disease diagnostics industry is at a pivotal juncture with robust innovations and expanding applications fueling business growth. Increasing global health concerns and advancements in diagnostic technologies are reshaping the industry dynamics, driving substantial market revenue growth and expanding the overall market scope.
Market Size and Overview
The global Infectious Disease Diagnostics market size is estimated to be valued at USD 1,750.8 million in 2025 and is expected to reach USD 3,370.8 million by 2032, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2025 to 2032.
Infectious Disease Diagnostics Market Forecast underscores significant growth opportunities driven by improved diagnostic accuracy and faster turnaround times. Market trends indicate rising adoption of point-of-care testing and molecular diagnostics as key growth accelerators. The market report reveals expanding investment across emerging regions and increasing demand for personalized diagnostic solutions.
Market Segments
The Infectious Disease Diagnostics market can be segmented into three primary categories:
- By Technology: Molecular diagnostics, immunodiagnostics, and culture-based diagnostics. Molecular diagnostics dominates with rapid and sensitive detection capabilities, capturing significant market revenue in 2024, while immunodiagnostics is the fastest-growing sub-segment due to advances in antibody-based testing.
- By Application: Viral infections, bacterial infections, and fungal infections. Viral infection diagnostics led revenue in 2024 following expanding testing for diseases like COVID-19 and HIV, whereas bacterial infection diagnostics is witnessing the fastest growth owing to rising antibiotic resistance concerns.
- By End User: Hospitals, diagnostic laboratories, and point-of-care testing centers. Hospitals remain the dominant end user, but point-of-care testing centers are the fastest growing, driven by demand for decentralized testing and rapid diagnostics during infectious disease outbreaks.
Market Drivers
A critical market driver is the increased investment in molecular diagnostics fueled by health policies emphasizing early detection and infectious disease management. For example, in 2024, government initiatives in the U.S. and Europe boosted molecular testing capacities by 22%, accelerating market growth. The introduction of next-generation sequencing and CRISPR-based diagnostics in 2025 further amplified treatment precision, aligning with market insights pointing to enhanced disease surveillance as a catalyst.
Segment Analysis
Focusing on technology type, molecular diagnostics continues to dominate both market size and market revenue through 2025. Case studies from diagnostic companies highlight that rapid PCR and isothermal amplification techniques saw revenue jumps exceeding 18% in 2024, driven by demand for COVID-19 variant detection. Immunodiagnostics, boosted by high-throughput serological assays, is showing faster revenue growth at 13% CAGR, indicating promising market opportunities reflecting evolving disease detection trends.
Consumer Behaviour Insights
Recent data reveals notable shifts in end-user behavior in the infectious disease diagnostics market. Firstly, there is increased digital consumption with clinicians and labs favoring integrated diagnostic platforms for real-time data access, supported by a 2024 survey reporting 40% of diagnostic labs adopted cloud-based diagnostic tools. Secondly, end users are demonstrating heightened pricing sensitivity due to budget constraints, influencing procurement decisions towards cost-effective multiplex testing kits. Lastly, customization preferences have gained momentum, with healthcare providers opting for tailored diagnostic assays aligned with specific population needs, highlighted by the launch of regional pathogen-specific panels in 2025.
Key Players
Key market players driving the Infectious Disease Diagnostics market growth include Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, bioMérieux, Hologic Inc., Qiagen, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Danaher Corporation, F. Hoffmann-La Roche AG, and Luminex Corporation. Notably, in 2024, Becton Dickinson expanded its molecular diagnostics capacity in Asia-Pacific, resulting in 15% revenue growth. Cepheid launched multiplex infectious disease panels in 2025, leading to enhanced market penetration. Abbott Laboratories introduced rapid COVID-19 home testing kits, significantly boosting consumer accessibility.
Key Winning Strategies Adopted by Key Players
Among distinctive growth strategies, Cepheid’s 2025 launch of multiplex PCR assays combining respiratory and gastrointestinal pathogen testing addressed a critical market opportunity, raising its regional penetration by 12%. Meanwhile, Becton Dickinson’s 2024 adoption of AI-based diagnostic algorithms enhanced diagnostic accuracy and workflow efficiency, demonstrating a 20% reduction in false positives. Abbott Laboratories pioneered a subscription-based procurement model in 2025 that improved customer retention and stabilized cash flows, an approach less commonly adopted yet highly impactful in business growth.
FAQs
1. Who are the dominant players in the Infectious Disease Diagnostics market?
Leading companies include Becton Dickinson & Company, Cepheid, Inc., and Abbott Laboratories, among others, which have driven market growth through product innovation and regional expansions in 2024 and 2025.
2. What will be the size of the Infectious Disease Diagnostics market in the coming years?
The market is projected to grow from USD 1,750.8 million in 2025 to approximately USD 3,370.8 million by 2032, reflecting a CAGR of 9.8%.
3. Which end user industry has the largest growth opportunity?
Point-of-care testing centers show the fastest growth potential due to increasing demand for rapid and accessible diagnostics during infectious disease outbreaks.
4. How will market development trends evolve over the next five years?
Trends point to expanded adoption of molecular diagnostics, integrated digital platforms, and personalized testing solutions, fueling sustained market revenue increases through 2032.
5. What is the nature of the competitive landscape and challenges in the Infectious Disease Diagnostics market?
The competitive landscape is marked by innovation-led strategies, capacity expansions, and technological integrations. Challenges include pricing pressures and regulatory compliance complexities.
6. What go-to-market strategies are commonly adopted in the Infectious Disease Diagnostics market?
Market players leverage new product launches, AI-enhanced diagnostics, subscription models, and regional market entries to drive revenue growth and expand market presence.
‣ Get more insights on : Infectious Disease Diagnostics Market
‣ Get this Report in Japanese Language: 感染症診断市場
‣ Get this Report in Korean Language: 감염병진단시장
‣Read More Articles Related to this Industry: How Genetic Testing is Revolutionizing Disease Prevention?
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
#Infectious Disease Diagnostics
#Diagnostics Market
#Medical Diagnostics
#Healthcare Market
#Coherent Market Insights
copyright src="chrome-extension://fpjppnhnpnknbenelmbnidjbolhandnf/content_script_web_accessible/ecp_regular.js" type="text/javascript">